Q3 2019 13F Holders as of 9/30/2019
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
132M
-
Number of holders
-
269
-
Total 13F shares, excl. options
-
107M
-
Shares change
-
+1.92M
-
Total reported value, excl. options
-
$8.59B
-
Value change
-
+$172M
-
Put/Call ratio
-
0.66
-
Number of buys
-
136
-
Number of sells
-
-118
-
Price
-
$80.42
Significant Holders of ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) as of Q3 2019
348 filings reported holding ALNY - ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK as of Q3 2019.
ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) has 269 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 107M shares
of 132M outstanding shares and own 81.2% of the company stock.
Largest 10 shareholders include FMR LLC (16.7M shares), WELLINGTON MANAGEMENT GROUP LLP (14.8M shares), VANGUARD GROUP INC (10.2M shares), BAILLIE GIFFORD & CO (8.24M shares), BlackRock Inc. (7.11M shares), Dodge & Cox (5.31M shares), PRICE T ROWE ASSOCIATES INC /MD/ (4.88M shares), MAVERICK CAPITAL LTD (3.22M shares), STATE STREET CORP (3M shares), and Bellevue Group AG (1.97M shares).
This table shows the top 269 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.